Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas
- PMID: 26748215
- DOI: 10.1016/j.ygyno.2015.12.031
Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas
Abstract
Objective: Somatic POLE mutations have been found in a subset of endometrioid ECs particularly in FIGO grade 3 tumors while POLD1 mutations are reportedly rare in ECs. While it has been suggested that POLE mutation confers good prognosis, the data remains conflicting. Our study aims to determine the mutation spectrum of somatic and germline POLE and POLD1 gene mutations in South East Asian (SEA) women with FIGO grade 3 endometrioid ECs.
Methods: Forty-seven patients diagnosed with FIGO grade 3 endometrioid EC, diagnosed between 2009 and 2013 were included. Next generation sequencing (NGS) using formalin fixed embedded (FFPE) tissue was utilized to sequence tumor and matched normal tissue. Tumors were also assessed for other clinicopathologic and microsatellite status phenotype. Survival curves for pathogenic somatic POLE mutated and wild-type tumors were estimated by Kaplan-Meier method.
Results: Pathogenic POLE (somatic or germline) and POLD1 (germline) mutations were detected in 29.7% (14/47) and 4.3% (2/47) patients, respectively. Three pathogenic germline mutations; one POLE and two POLD1 mutations were novel. Pathogenic germline and somatic POLE and POLD1 mutations were associated with 100% recurrence free survival. In contrast, among the wild-type POLE and POLD1 patients, 25% (8/32) had recurrence with 15.6% (5/32) subsequently dying of the disease. Somatic POLE-mutated tumors were more commonly associated with microsatellite stable (MSS) ECs (83% vs 49%; p=0.04) and peritumoral lymphocytic infiltration (75% vs 42%; p=0.05). All tumors with tumoral infiltrating lymphocytes exhibited peritumoral lymphocytic infiltrate but not vice versa.
Conclusion: Mutations in POLE and POLD1 in SEA women with grade 3 endometrioid ECs are associated with improved recurrence free survival. Notably, germline mutations in either POLE/POLD1 were seen in 8.5% of patients who will require appropriate genetic counseling regarding risk of developing colorectal carcinoma and on the need for additional surveillance for colonic changes. MSS and peritumoral lymphocytic infiltration may be useful histological features for distinguishing POLE mutated grade 3 endometrioid ECs.
Keywords: Asian; Endometrial cancer; Germline; POLD1; POLE.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.Gynecol Oncol. 2014 Jul;134(1):15-9. doi: 10.1016/j.ygyno.2014.05.006. Epub 2014 May 16. Gynecol Oncol. 2014. PMID: 24844595
-
Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.Histopathology. 2016 May;68(6):916-24. doi: 10.1111/his.12878. Epub 2015 Dec 17. Histopathology. 2016. PMID: 26416160 Free PMC article.
-
Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.Histopathology. 2018 Jan;72(2):248-258. doi: 10.1111/his.13338. Epub 2017 Oct 10. Histopathology. 2018. PMID: 28795426
-
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.Gynecol Oncol. 2024 Mar;182:99-107. doi: 10.1016/j.ygyno.2024.01.018. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262245 Free PMC article.
-
The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.PLoS One. 2022 Feb 9;17(2):e0263585. doi: 10.1371/journal.pone.0263585. eCollection 2022. PLoS One. 2022. PMID: 35139130 Free PMC article.
Cited by
-
Elevated expression of POLD1 is associated with poor prognosis in breast cancer.Oncol Lett. 2018 Nov;16(5):5591-5598. doi: 10.3892/ol.2018.9392. Epub 2018 Sep 4. Oncol Lett. 2018. PMID: 30344713 Free PMC article.
-
POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.Gene. 2016 Sep 15;590(1):128-41. doi: 10.1016/j.gene.2016.06.031. Epub 2016 Jun 16. Gene. 2016. PMID: 27320729 Free PMC article. Review.
-
Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.DNA Repair (Amst). 2017 Aug;56:16-25. doi: 10.1016/j.dnarep.2017.06.003. Epub 2017 Jun 9. DNA Repair (Amst). 2017. PMID: 28687338 Free PMC article. Review.
-
Incomplete Segregation of MSH6 Frameshift Variants with Phenotype of Lynch Syndrome.Int J Mol Sci. 2017 May 6;18(5):999. doi: 10.3390/ijms18050999. Int J Mol Sci. 2017. PMID: 28481244 Free PMC article.
-
Phenotype of POLE-mutated endometrial cancer.PLoS One. 2019 Mar 27;14(3):e0214318. doi: 10.1371/journal.pone.0214318. eCollection 2019. PLoS One. 2019. PMID: 30917185 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources